Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 29, 2007
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. The company operates through two reportable segments: Healthcare Distribution (dental, medical, animal health, and international) and Technology (practice management software and value-added services). It serves over 550,000 customers worldwide with a workforce of more than 12,000 employees.
Key Financial Metrics
| Metric | 2007 (in thousands) | 2006 (in thousands) |
|---|---|---|
| Net Sales | $5,920,190 | $5,048,191 |
| Gross Profit | $1,718,284 | $1,471,957 |
| Gross Margin | 29.0% | 29.2% |
| Operating Income | $386,259 | $304,135 |
| Net Income | $215,173 | $163,759 |
| Diluted EPS (Continuing Ops) | $2.58 | $2.03 |
| Operating Cash Flow | $270,211 | $235,317 |
| Total Debt | $456,570 | $499,370 |
| Working Capital | $908,160 | $834,760 |
| Cash and Equivalents | $247,590 | $248,647 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17.3% to $5.92 billion, driven by 14.3% local currency growth (7.3% organic, 7.0% acquisitions) and a 3.0% foreign currency exchange benefit.
- Segment Performance:
- International: Sales grew 26.2%, fueled by 16.6% local currency growth (12.3% from acquisitions) and 9.6% currency exchange.
- Dental: Sales grew 15.2%, with equipment sales and service up 25.0%.
- Technology: Sales grew 34.3%, driven by electronic services and financial services.
- Profitability: Operating income rose 27.0% to $386.3 million. Net income increased 31.4% to $215.2 million. The effective tax rate decreased to 34.0% from 35.6% due to tax planning and foreign income mix.
- Discontinued Operations: The company sold its oncology pharmaceutical and specialty pharmacy businesses in 2007, resulting in a net gain of $0.7 million, compared to a $19.4 million loss on the sale of the Hospital Supply Business in 2006.
- Debt Reduction: Total debt decreased by approximately $42.8 million due to principal repayments on senior notes.
Guidance, Outlook, and Risks
- Outlook: Management expects the effective tax rate for 2008 to range between 34% and 35%. Capital expenditures for 2008 are projected at $50.0 to $55.0 million for facility modernization and system integration.
- Strategic Focus: Continued expansion through acquisitions and joint ventures, increasing penetration of existing customers, and leveraging value-added technology services.
- Key Risks:
- Regulatory: Compliance with complex federal and state laws regarding pharmaceutical distribution (e.g., drug pedigree requirements) and healthcare fraud.
- Competition: Intense competition from other distributors and manufacturers selling directly to end-users.
- Supply Chain: Dependence on third-party suppliers for substantially all products; potential for supply interruptions.
- Market Volatility: Fluctuations in quarterly earnings due to seasonality, foreign currency exchange rates, and interest rate changes.
Investor Verification Checklist
- Acquisition Integration: Verify the successful integration of major 2007 acquisitions (W&J Dunlop, Software of Excellence, Becker-Parkin) and the realization of projected synergies.
- Discontinued Operations: Confirm the final financial impact and closure of the oncology and specialty pharmacy divestitures.
- Regulatory Compliance Costs: Monitor costs associated with new drug pedigree and track-and-trace regulations (e.g., California RFID requirements effective 2009).
- Debt Covenants: Review adherence to leverage and interest coverage ratios required by senior notes and credit facilities.
- Foreign Currency Exposure: Assess the impact of currency fluctuations on the significant international revenue stream (approx. 30% of total sales).